Контривен 10 000 КИЕ/мл 5 мл раствор для инъекций

Nazione: Kirghizistan

Lingua: russo

Fonte: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Principio attivo:

Апротинин

Commercializzato da:

ФЗ Биофарма ООО (ФЗ Биофарма ООО)

Codice ATC:

B02AB01

INN (Nome Internazionale):

Aprotinin

Dosaggio:

10 000 КИЕ/мл 5 мл

Forma farmaceutica:

раствор для инъекций

Confezione:

№5

Tipo di ricetta:

по рецепту

Prodotto da:

ФЗ Биофарма ООО (Украина)

Dettagli prodotto:

ПЖВЛС: нет

Data dell'autorizzazione:

2016-06-23

Scheda tecnica

YTBEPXAAIO
fenepa;rrnufi
gupexrop
pcTBeHHOIO
TEXHIIKII
paHeHHfl
y6rnrcu
r4HCTpyKt\Ltfl
TToMEAT4IIIIHCKOMyTTPIIMEHEHTIIOJIEKAPCTBEHHOTO
CPENCTBA
KOHTPIIBEH
(coNTRYVEN)
Cocmse:
deilcmeynuqe
e seule
cmso
: ailpornlr.nH;
1 ur
pacreopa
coAepxnr: 10000
KI4E auporvlr.nna;
gcnoMoz0merbHbte
6eu4ecmga:
HuTpIlfl xnoprlA,
BoAa
Ant
uHrexuufi.
Jlexapcrnennar
Qopua.
Pacreop
4rr
Iauterqufi.
Ocuoeuute
Qusurco-xuuuqecKue
ceoilcmea:
npo3paqHar,
6ecqnernar
vlru c )I(eJIToBarbIM
orreHKoM
XI,I.[KOCTb.
@ap n arcorep
a neBTH
q
ecKas rpyrn
a.
Vluru6ur opbl nporel.IHas.
Anporuuuu.
Koa
ATX B02A 801,
@apuarco.norrrrrecKr.re
csofi crea.
@apuarcoduHaMuKa.
Anporuuuu
npeAcraBnrer
co6ofi
MoneKyny zHrz6zropa
flporea3 IIII4poKoro crleKTpa
geitcryut,
o6laAaer
anrn$u6prznoluruqnofi
aKTr4BHocrbro. O6pasy.a
o6parultufi
crexl4oMerplaqecrplfi
KoMnJreKc
(fepuenr-unru6zrop,
anporr4Hr4H
y
qeJroBeKa
uutu6upyer
rprrnclrH,
rrJra3Mr{H,
KannvKper4H
B nJriBMe
KpoBr4
pr
rKarurx,
r{To
npr4BoAur
x unrn6npoBaHprro
(pn6pnnorusa.
Kponae
roro,
oH
uuru6upyer
KoHTaKTHyro
(pasy
aKTVBa\vpt
cBeprbrBaHru
KpoBr{,
Koropa.f,
rBJr.flercq
tf arropo u 3arrycKa
npo
qecca
Koarymquu
rI crl4Myn
rr,ryu
$u6pLIHo
JILI3a.
AuporuHuu
npr4MeH.sercr
Bo BpeMr;
onepaqnft
B
ycnoBprrx
rlcKyccrBeHHoro
KpoBoo6paqenux,
rrocKonbKy on ocra6r.f,er BocrraJrr4TeJrbHbre
peaKrlr4r4,
r{To
npr4BoAt'rr
K cHr4}KeHr{ro
norpe6uocru
n
rpanc(fysuu
arlorennofi
KpoBr{
14 cHr4xeHr.r}o
KpoBonorepr4,
a
raKx(e
K
yMeHbrxeHnro
ueo6xo4rauocrr4
noBTopHoro
r4ccJreAoBaHzr
cpeAocreHrrr
rro noBoAy KpoBoretreHr4r.
Y
naquenroB,
KoropbrM rrpoBoArrnacb
oneparluq
aoproKopoHapHoro
[ryHTt4poBaHurs,
qacrora
rroBbrlreHuJr
ypoBHq
KpearrrHr{Ha
B cbrBoporKe
KpoBH ua 0,5 ur/Ar
no cpaBHeHHIo
c ucxoAHbrM
ypoBHeM
6ura
4ocroBepHo
Bbrrrre
y
[aqr.reHToB, rroJryrrr4Brru4x
nonHyro
Ao3y
ailporr4Hr4Ha
rro
cpaBHeHr{ro
c
rpynnofi
nraqe6o.
B
6o:rruruncree
cnfraeB
nocneonepaqrroHHoe
HapyrneHr4e
$ynxquu
roqeK Hocr4Jro
o6parralrufi xapaKTep
u ue 6ulo
cepbe3HbrM;
qacrora
rroBbrrrreHr{r
ypoBHt
cbrBoporoqHofo KpearvtHuHa rro orHorrreHr4ro
K r4cxoAHoMy
ypoBHro